Ji J, Liu Z, Kuang P, et al. - The proposed chidamide-cladribine-gemcitabine-busulfan combination therapy is a safe and valid new conditioning therapy for high-risk and refractory/relapsed lymphomas.

• This phase II trial involved 105 patients: 60 with B-cell non-Hodgkin lymphomas (B-NHL), and 45 with T-cell, or natural killer/T-cell lymphoma (NK/T).

• Patients with high-risk, relapsed/refractory lymphomas were administered chidamide, cladribine, gemcitabine, and busulfan as conditioning therapy, following transplantation with autologous peripheral stem cells.

• Full hematopoietic recovery was gained in all cases.

• Non-hematologic toxicities included neutropenic fever, mucositis, and atopic dermatitis.

• A median follow-up of 35.4 months revealed no tumor progression in 80.6% of the patients, and overall survival was as high as 86.1%.

• Patients who survived included 94.5% of patients with B-NHL and 75.4% of patients with T-cell or NK/T lymphomas.